Aceragen, Inc. (ACGN) 2005年年度报告「NASDAQ」.pdf

1、Innovative Ideas to Treat Disease in a New Era of Targeted Immune TherapyA N N U A L R E P O R T 2 0 0 5Today,Idera is focused ondevelopment of targetedimmune therapy for abroad range of diseases,and is poised to capitalizeon the promise of excitingtherapeutic opportunities.T O O U R S T O C K H O L

2、 D E R S:2005 was a pivotal year for our Company in which we accomplished several defining milestones,including the creation of a new identity for our Company as Idera Pharmaceuticals,Inc.Our own research and recent industry and scientific developments validate our belief in the promise of targeted

3、immune therapy.We believe that targeted immune therapywill play an important role in treating various diseases including cancer,infectious diseases,allergy,and asthma.Our rationale for focusing on targeted immune therapy is supported by our extensive experience gained through the application of DNA

4、chemistry to drug discovery.Our strategy is reinforced by the hundreds of publications in scientific and trade journals that describe the critical role of Toll-like receptors(TLRs)in immunity and by our early clinical experience with antisense technology.We have designed novel DNA-based compounds th

5、at interact with specific members of the TLR family and produce a spectrum of immune responses.Major international pharmaceutical companies signed license or collaborationagreements in 2005 to gain access to products or programs based on TLR modulation for various disease indications,including oncol

6、ogy,infectious disease,and asthma/allergy.We participated in this licensing activity through an alliance with Novartis.In 2005,we aligned our human and capital resources to support the discovery,development,and partnering of our proprietary TLR-based programs and products.We put strategy,science,cli